Nvidia Partners with Eli Lilly in $1B AI Pharma Venture
Nvidia shares saw modest gains after announcing a $1 billion AI co-innovation lab with pharmaceutical leader Eli Lilly. The collaboration aims to revolutionize drug discovery by merging Nvidia's AI computing platforms with Lilly's pharmaceutical expertise.
The South San Francisco-based lab represents a five-year commitment, targeting accelerated drug development through predictive AI modeling. While operational details remain undisclosed, the venture signals growing institutional adoption of AI in biopharma.
Nvidia will contribute its BioNeMo system and Vera Rubin architecture, specialized tools for pharmaceutical AI applications. The partnership reflects broader industry trends as AI expands from research into clinical trials and supply chain optimization.